Post-Authorization Activity Table (PAAT) for Istodax

The PAAT describes post-authorization activity for Istodax, a product which contains the medicinal ingredient romidepsin. Istodax (romidepsin for injection), an antineoplastic agent, is indicated for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one prior systemic therapy. Read more here.